Leading Product Candidates
Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.
-
SPR994
Oral Candidate to Treat MDR Gram-Negative Infections
Novel antibiotic with potential to be the first oral carbapenem for use in adults in treating cUTI.
-
SPR720
Oral Candidate to Treat Non-tuberculous Mycobacterial Infections
Novel agent with the potential to be the first oral antibiotic approved for the treatment of NTM infections.
- Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
-
Investors
Learn about the investment opportunity, see our upcoming events and download our latest corporate presentation.
Investment opportunities > -
Careers
Join a passionate team that pushes the limits in finding innovative therapies to help patients. Named one of Boston’s Best Places to Work.
Career opportunities > -
Partners
Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.
Partnership opportunities >
